XML 85 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Insider Trading Arrangements
3 Months Ended 6 Months Ended
Jun. 30, 2024
shares
Jun. 30, 2024
shares
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement  
During the three months ended June 30, 2024, the Company’s six section 16 officers adopted written plan for the purchase or sale of Company securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). These plans were adopted on June 28, 2024, and are subject to a 90-day “cool off” period before any trades may be conducted under such plans.


NameTitlesAction TakenType of TradingNature of TradingExpiration DateAggregate Number of Securities
Christophe Arbet-EngelsChief Medical Officer
Adoption (June 28, 2024)
Rule 10b5-1 trading arrangementSale8/1/2025
(i) 572,917 shares of common stock subject to employee stock options and (ii) Indeterminable (2).
Mark BaldryChief Commercial Officer
Adoption (June 28, 2024)
Rule 10b5-1 trading arrangementSale10/1/2025Indeterminable (1)
Mary DiBiaseChief Operating Officer
Adoption (June 28, 2024)
Rule 10b5-1 trading arrangementSale10/1/2025Indeterminable (1)
Adam MostafaChief Financial Officer
Adoption (June 28, 2024)
Rule 10b5-1 trading arrangementSale10/1/2025Indeterminable (2)
Paula RaganPresident and Chief Executive Officer
Adoption (June 28, 2024)
Rule 10b5-1 trading arrangementSale10/1/2025
(i) 313,794 shares of common stock subject to long, restricted and control stock and (ii) Indeterminable (1)
Arthur TaverasChief Scientific Officer
Adoption (June 28, 2024)
Rule 10b5-1 trading arrangementSale10/1/2025Indeterminable (1)
(1) The number of shares that will be sold in accordance with this trading arrangement is indeterminable at the time of the filing of this Quarterly Report on Form 10-Q for the period ended June 30, 2024. Upon vesting of PRSUs, a sell-to-cover trade may occur or the Company may withhold shares in order to satisfy any applicable tax withholding obligations on behalf of the employee. The number of shares sold in the sell-to-cover will vary based on the market price of the Company’s common stock at the time of settlement.

(2) The number of shares that will be sold in accordance with this trading arrangement is indeterminable at the time of the filing of this Quarterly Report on Form 10-Q for the period ended June 30, 2024. Upon vesting of PRSUs, a sell-to-cover trade may occur or the Company may withhold shares in order to satisfy any applicable tax withholding obligations on behalf of the employee. The number of shares sold in the sell-to-cover will vary based on the market price of the Company’s common stock at the time of settlement. Any remaining shares held by the seller after the sell-to-cover may be sold pursuant to the terms of this trading arrangement.
.
Non-Rule 10b5-1 Arrangement Adopted false  
Rule 10b5-1 Arrangement Terminated false  
Non-Rule 10b5-1 Arrangement Terminated false  
Christophe Arbet-Engels [Member]    
Trading Arrangements, by Individual    
Name Christophe Arbet-Engels  
Title Chief Medical Officer  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date June 28, 2024  
Arrangement Duration 399 days  
Aggregate Available 572,917 572,917
Mark Baldry [Member]    
Trading Arrangements, by Individual    
Name Mark Baldry  
Title Chief Commercial Officer  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date June 28, 2024  
Arrangement Duration 460 days  
Mary DiBiase [Member]    
Trading Arrangements, by Individual    
Name Mary DiBiase  
Title Chief Operating Officer  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date June 28, 2024  
Arrangement Duration 460 days  
Adam Mostafa [Member]    
Trading Arrangements, by Individual    
Name Adam Mostafa  
Title Chief Financial Officer  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date June 28, 2024  
Arrangement Duration 460 days  
Paula Ragan [Member]    
Trading Arrangements, by Individual    
Name Paula Ragan  
Title President and Chief Executive Officer  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date June 28, 2024  
Arrangement Duration 460 days  
Aggregate Available 313,794 313,794
Art Taveras [Member]    
Trading Arrangements, by Individual    
Name Arthur Taveras  
Title Chief Scientific Officer  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date June 28, 2024  
Arrangement Duration 460 days